Pushkal Garg, CMO & EVP Development & Med Affairs at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 2,956 shares at $250.08 ($742K) on 2024-12-12, disclosed to the SEC on 2024-12-13.
Scheduled sale ($742k) by CMO & EVP Development & Med Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $247.48 | 121 | $30K | 4.0% |
| 2 | $248.99 | 186 | $46K | 6.2% |
| 3 | $250.08 | 426 | $107K | 14.4% |
| 4 | $250.08 | 426 | $107K | 14.4% |
| 5 | $251.68 | 778 | $196K | 26.4% |
| 6 | $251.68 | 778 |
| $196K |
| 26.4% |
| 7 | $252.94 | 100 | $25K | 3.4% |
| 8 | $254.37 | 140 | $36K | 4.8% |
| 9 | $255.80 | 1 | $256 | 0.0% |
| Total | $251.05 avg | 2,956 | $742K | 100% |
| Filing → |
| ALNY | SELL | 2026-03-02 | $1.5M | — | Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |